Уважаемые пользователи!
Мы рады представить вам новую версию сайта с улучшенным интерфейсом и новыми возможностями.
Приглашаем вас ознакомиться и поделиться обратной связью. Спасибо, что вы с нами!
Попробовать!
RUEN

ENGAGE AF-TIMI 48 subgroup: Amiodarone as adjunct to low-dose edoxaban reduces ischemic events

11.08.20151752
Patients in the ENGAGE AF-TIMI 48 trial who received amiodarone at randomization in addition to a lower-dose regimen of edoxaban experienced a reduction in ischemic events vs. warfarin compared with those on the lower-dose alone, according to research published in the European Heart Journal.

Study links statin use to lower mortality in RA patients

10.08.20151709
Among adults with rheumatoid arthritis, starting a statin prescription led to a 21% drop in risk of dying from any cause, compared with not using statins, according to a study published online Aug. 5 in Annals of the Rheumatic Diseases.

Triamterene-hydrochlorothiazide combination lowers BP

07.08.20151678
Researchers studied 17,291 patients with hypertension using data from the Indiana Network for Patient Care database (2004-2012).

Extracranial Systemic Embolic Events in Patients with Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes

06.08.20151720
Nonvalvular atrial fibrillation (AF) is a major cause of thromboembolic events. Compared to AF-related stroke, extracranial systemic embolic events (SEE) remain poorly defined.

Triple therapy has similar outcomes, more bleeding than dual therapy in older patients

05.08.20151621
Researchers analyzed 4,959 patients aged 65 years or older from the Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With the Guidelines.

High CRP predicts long-term mortality, MI after PCI

04.08.20151787
Higher levels of C-reactive protein at the time of PCI were predictive of all-cause mortality and MI at 10 years, researchers reported in a new study.

Enrollment begins for two trials of dabigatran

03.08.20151659
The first U.S. patients have been enrolled in the RE-DUAL PCI and RE-CIRCUIT trials of the safety and efficacy of dabigatran in patients with nonvalvular atrial fibrillation, according to a press release from Boehringer Ingelheim.
123...2324252627...153154155
Enter the Society
Subscribe to Newsletter
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.